Joe Rogan’s Peptide Use, Fact-Checked
Joe Rogan says he uses BPC-157 and TB-500 to heal injuries. We fact-check the claims against the actual literature — what holds up, what doesn't.
Joe Rogan has repeatedly named BPC-157 and TB-500 as the peptides he uses for injury recovery. The claim about which peptides he says he uses is accurate. The claim that they are proven to rebuild tendons in people is not — that evidence is almost entirely animal work.
Joe Rogan is now one of the most-heard voices on research peptides, and he is specific about which ones he uses. After rupturing his Achilles on an elk hunt in September 2025, he described his rehab stack in a single sentence: “BPC-157 and TB-500 — that’s it,” delivered by local injection into the injured tissue.1 He has told guests to “get immediately on BPC-157 and TB-500” if they ever get hurt, calling it the “Wolverine stack.”2 The which-peptides part of his story checks out cleanly. The does-it-do-what-he-says part is where the literature and the podcast diverge. Everything below describes laboratory and literature findings, not use in people.
What did Rogan actually claim?
The claims are documented across several 2025–2026 episode write-ups with direct quotes. On the peptides themselves, Rogan is unambiguous: BPC-157 and TB-500, favoring local injection over systemic delivery (“I think local is the way to go”).1 On the Joe Rogan Experience with Ben Affleck and Matt Damon, he pushed further — “if you ever get injured, get immediately on BPC-157 and TB-500” — branded it the “Wolverine stack,” and reached as far as claims of neuro-regeneration for brain damage.2 Elsewhere he has said BPC-157 cleared his elbow tendonitis “in two weeks,” and defended the whole category by citing “peer-reviewed studies on BPC-157… a very clear pathway.”3
So the attribution is solid: he says these things, repeatedly and on the record. The nickname is worth flagging early. The “Wolverine stack” originated in online biohacking and fitness communities, riffing on the comic-book character’s regeneration. It is marketing folklore, not a scientific designation.
0 completed randomized human trials support BPC-157 for the tendon and muscle recovery Rogan describes.
What are these two molecules, structurally?
They are not the same kind of thing, and conflating them is the first place the popular story gets loose. BPC-157 is a synthetic 15-amino-acid “pentadecapeptide” whose sequence is derived from a partial fragment of a protein found in human gastric juice. TB-500 is a synthetic fragment of thymosin β4, a naturally occurring 43-amino-acid regenerative protein. The evidence bases sit in different places, and — crucially for the fact-check — TB-500 is not identical to the thymosin β4 that has actually been studied in people.
The mechanistic story Rogan and Andrew Huberman have told on the podcast is roughly accurate as a description of the preclinical hypothesis. BPC-157 is proposed to act as a “repair signal” that recruits fibroblasts and promotes angiogenesis, partly through the nitric-oxide system, to rebuild soft tissue. There is real animal work behind that framing. In vitro and in rats, BPC-157 has been reported to accelerate tendon fibroblast outgrowth, survival and migration,4 to enhance angiogenesis during tendon and muscle healing,5 and to improve recovery in a transected-muscle model.6 The mechanism is not invented. What is missing is the leap from that mechanism to a human standing in a gym.
The mechanism is real in rats. The human proof Rogan implies does not exist yet.
Claim-by-claim
| Rogan’s claim | What the literature actually shows |
|---|---|
| “BPC-157 and TB-500 — that’s it” (which peptides he uses) | Accurate as attribution. He says this repeatedly and specifically.1 |
| BPC-157 rebuilds tendon/muscle in people | Not supported. Evidence is preclinical animal and in-vitro only; an independent 2025 review found no supporting human trials.7 |
| “Peer-reviewed studies… a clear pathway” | Partly true. Peer-reviewed rat studies exist,4 but they are animal work, and much of the enthusiastic literature is from one research lineage.9,10 |
| TB-500 heals tendons and hamstrings | Bait-and-switch. Human data is for topical thymosin β4 on skin ulcers, not injected TB-500 into tendons.11,12 |
| “USADA banned it, so it works” | Logical fallacy. Bans track unproven and unsafe substances too; a ban is not evidence of efficacy. |
| BPC-157 is basically a medicine | No. It is unapproved and investigational everywhere.8 |
All efficacy entries refer to in-vitro or animal studies except where thymosin β4 human ulcer data is noted; none establishes efficacy for injected human sports-injury recovery. Research Use Only.
An honest read of the evidence
Here is the part the podcast clips leave out. Nearly all of the BPC-157 efficacy evidence is in rats and in cultured cells. For the exact use Rogan promotes — tendon, muscle and injury recovery in humans — there are essentially zero completed randomized human trials. An independent 2025 systematic review in the HSS Journal, notably not authored by the peptide’s originating group, reviewed the orthopaedic sports-medicine literature and concluded that the evidence is almost entirely preclinical and that clinical use is not yet supported.7 A 2026 review framed BPC-157 as still investigational, with formulation and translational barriers unresolved and no completed human efficacy trials.8
There is a second, quieter problem: lineage. A large share of the enthusiastic BPC-157 literature — including broad wound-healing reviews and much of the tendon and muscle work — originates from or is associated with a single research group (the Sikiric/Seiwerth lab in Zagreb).5,9,10 That does not make the findings wrong, but concentration in one lab, without robust independent Western replication of the dramatic healing effects, is exactly the pattern that should slow you down before treating a result as settled. The closest thing to human exposure is early BPC-157 (as PL 14736) trials for inflammatory bowel disease14 — a different indication that never produced an approved drug.
TB-500 has its own sleight of hand. The genuine human-adjacent data belongs to thymosin β4, TB-500’s parent protein, applied topically to skin wounds — pressure and venous ulcers — where it accelerated dermal healing in animal models and early patient studies.11,12 Thymosin β4’s mechanisms in that setting (cell migration, angiogenesis, anti-inflammatory action) are reasonably characterized,12 and it has been explored across several therapeutic areas without reaching routine approved clinical use.13 None of that is the same as a synthetic fragment injected into a tendon. Extrapolating skin-ulcer topical data to injected athletic recovery is not an evidence-based move; it is a hopeful one.
Then there are the testimonials. Rogan’s strongest evidence is anecdotal and self-experimental: elbow tendonitis “gone in two weeks,” a football player’s hamstring back in a fraction of the expected time.2,3 Those stories are uncontrolled, unblinded, and confounded by the simple fact that tendons and hamstrings heal on their own over weeks. The one argument that should be retired outright is “USADA banned it, so it works.” Anti-doping bodies prohibit substances for many reasons, including unproven efficacy and unknown safety. A prohibition is a regulatory decision, not a clinical result. Finally, the products sold under these names are unregulated research chemicals; identity, purity and consistency are not quality-controlled by any medicines regulator, and no long-term human safety data exists.
All materials supplied by Condor Research are Research Use Only (RUO). Everything above is science commentary drawn from published in-vitro, animal and literature findings, not a dosing protocol, clinical guidance, endorsement, or safety assessment for any organism. Nothing here concerns human or veterinary use, and nothing here is advice to acquire, administer or self-experiment with any compound.
Condor Research · Scientific desk
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com
- Rogan has explicitly and repeatedly named BPC-157 and TB-500 as his recovery peptides, most concretely as his 2025 Achilles-rehab stack delivered by local injection.
- The 'Wolverine stack' nickname comes from online biohacking communities, not from any scientific source.
- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric-juice protein sequence; TB-500 is a synthetic fragment of the natural protein thymosin β4 — they are different molecules with different evidence bases.
- An independent 2025 systematic review found the orthopaedic evidence for BPC-157 is essentially all preclinical animal work, with no supporting human clinical trials.
- The strongest human-adjacent peptide data is for thymosin β4 applied topically to skin ulcers — not for injected TB-500 into tendons.
- BPC-157 is not an approved drug anywhere and remains investigational; products sold under these names are unregulated research chemicals.
- Rogan's 'USADA banned it because it works' argument is a logical fallacy — anti-doping bans track unproven and unsafe substances too.
Did Joe Rogan really say he uses BPC-157 and TB-500?
Yes. He has named both repeatedly on the podcast. His most concrete statement came after his 2025 Achilles rupture, when he described his rehab stack as "BPC-157 and TB-500 — that's it," delivered by local injection. He also urged guests to "get immediately on BPC-157 and TB-500" if injured.
So is he wrong about the peptides working?
He is right about which peptides he uses and right that peer-reviewed studies exist. He overstates what those studies show. For the tendon and muscle recovery he promotes, the human evidence is essentially absent — an independent 2025 systematic review found the BPC-157 orthopaedic literature is almost entirely animal work.
What about the "Wolverine stack" name?
It is an internet nickname from biohacking and fitness communities, not a scientific term. It borrows the X-Men character's regeneration as a metaphor and carries no clinical meaning.
Is TB-500 the same molecule that has human data?
No, and this is a common confusion. TB-500 is a synthetic fragment of thymosin β4. The human clinical data belongs to thymosin β4 applied topically to skin ulcers, not to injected TB-500 for tendons. Treating the two as interchangeable is not supported by the evidence.
Does the anti-doping ban prove efficacy?
No. That is a logical fallacy. Anti-doping agencies also ban substances with unproven efficacy and unknown safety profiles. The ban reflects policy and precaution, not a demonstration that the substance rebuilds tissue in humans.
Where can I read the underlying science?
Our companion explainers cover what BPC-157 is, what TB-500 is, and how the two compare. We ran the same fact-check on Andrew Huberman's peptide claims, and cover the wound-healing peptide GHK-Cu separately.